RESUMEN
OBJECTIVE: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are rare small to medium-size vessel systemic diseases. As their clinical picture, organ involvement, and factors influencing outcome may differ between countries and geographical areas, we decided to describe a large cohort of Polish AAV patients coming from several referral centers-members of the Scientific Consortium of the Polish Vasculitis Registry (POLVAS). METHODS: We conducted a systematic multicenter retrospective study of adult patients diagnosed with AAV between Jan 1990 and Dec 2016 to analyze their clinical picture, organ involvement, and factors influencing outcome. Patients were enrolled to the study by nine centers (14 clinical wards) from seven Voivodeships populated by 22.3 mln inhabitants (58.2% of the Polish population). RESULTS: Participating centers included 625 AAV patients into the registry. Their distribution was as follows: 417 patients (66.7%) with GPA, 106 (17.0%) with MPA, and 102 (16.3%) with EGPA. Male-to-female ratios were almost 1:1 for GPA (210/207) and MPA (54/52), but EGPA was twice more frequent among women (34/68). Clinical manifestations and organ involvement were analyzed by clinical phenotype. Their clinical manifestations seem very similar to other European countries, but interestingly, men with GPA appeared to follow a more severe course than the women. Fifty five patients died. In GPA, two variables were significantly associated with death: permanent renal replacement therapy (PRRT) and respiratory involvement (univariate analysis). In multivariate analysis, PRRT (OR = 5.3; 95% confidence interval (CI) = 2.3-12.2), respiratory involvement (OR = 3.2; 95% CI = 1.06-9.7), and, in addition, age > 65 (OR = 2.6; 95% CI = 1.05-6.6) were independently associated with death. In MPA, also three variables were observed to be independent predictors of death: PRRT (OR = 5.7; 95% CI = 1.3-25.5), skin involvement (OR = 4.4; 95% CI = 1.02-19.6), and age > 65 (OR = 6.3; 95% CI = 1.18-33.7). CONCLUSIONS: In this first multicenter retrospective study of the Polish AAV patients, we have shown that their demographic characteristics, disease manifestations, and predictors of fatal outcome follow the same pattern as those from other European countries, with men possibly suffering from more severe course of the disease.
Asunto(s)
Vasculitis Asociada a Anticuerpos Citoplasmáticos Antineutrófilos/diagnóstico , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Polonia , Pronóstico , Sistema de Registros , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Factores Sexuales , Evaluación de SíntomasRESUMEN
Transplant recipients have been identified as a new risk group for microsporidia infection. We characterize for the first time the prevalence of microsporidia in intestinal and urinary tracts of renal transplant recipients. Molecular examination of 86 patients showed that 25.5% of them were infected; 86% were confirmed to have pathogens in their urine and 45.5% in stool. Among positive patients, 32% had microsporidia confirmed in both urine and stool. Genotyping revealed Encephalitozoon cuniculi (59%) and Enterocytozoon bieneusi (23%) monoinfections as well as coinfections with both species (18%). Moreover, we found diarrhoea and fever as symptoms significantly associated with microsporidia presence. Our results indicate that microsporidial infection should be considered in the assessment of renal transplant recipients, especially in the urinary tract, even if asymptomatic. Molecular identification of microsporidia species is relevant because of their different susceptibility for treatment.
Asunto(s)
Trasplante de Riñón , Microsporidios/clasificación , Microsporidios/genética , Microsporidiosis/epidemiología , Microsporidiosis/microbiología , Receptores de Trasplantes , Adolescente , Adulto , Anciano , Diarrea/epidemiología , Diarrea/microbiología , Heces/microbiología , Femenino , Técnicas de Genotipaje , Humanos , Masculino , Microsporidios/aislamiento & purificación , Persona de Mediana Edad , Prevalencia , Infecciones Urinarias/epidemiología , Infecciones Urinarias/microbiología , Orina/microbiología , Adulto JovenAsunto(s)
Glomerulonefritis/diagnóstico , Glomerulonefritis/virología , Hepatitis C/complicaciones , Hepatitis C/diagnóstico , Lupus Eritematoso Sistémico/diagnóstico , Adulto , Antivirales/uso terapéutico , Diagnóstico Diferencial , Femenino , Glomerulonefritis/tratamiento farmacológico , Hepatitis C/tratamiento farmacológico , Humanos , Inmunosupresores/uso terapéutico , Interferones/uso terapéutico , Metilprednisolona/uso terapéutico , Ribavirina/uso terapéutico , Resultado del TratamientoAsunto(s)
Glomerulonefritis Membranosa/tratamiento farmacológico , Inmunosupresores/efectos adversos , Sarcoma de Kaposi/tratamiento farmacológico , Sirolimus/análogos & derivados , Neoplasias Cutáneas/tratamiento farmacológico , Anciano , Biopsia con Aguja , Everolimus , Femenino , Estudios de Seguimiento , Glomerulonefritis Membranosa/complicaciones , Glomerulonefritis Membranosa/diagnóstico , Humanos , Inmunohistoquímica , Inmunosupresores/administración & dosificación , Pruebas de Función Renal , Sarcoma de Kaposi/inmunología , Sarcoma de Kaposi/patología , Índice de Severidad de la Enfermedad , Sirolimus/uso terapéutico , Neoplasias Cutáneas/inmunología , Neoplasias Cutáneas/patología , Resultado del TratamientoRESUMEN
Antibodies against monomeric C-reactive protein, which is a target antigen expressed both in kidney tubules and uveal cells, have been recently detected in patients with active tubulointerstitial nephritis and uveitis syndrome. We report the case of an 65-year-old woman with acute renal failure caused by biopsy-proven tubulointerstitial nephritis and the onset of uveitis 21 months later. The expression of monomeric C-reactive protein in kidney oligobiopsy was confirmed by immunohistochemical staining using mouse monoclonal antibody against human monomeric C-reactive protein. The levels of antibodies against monomeric C-reactive protein were 117% of the reference during the flare and 22% during the remission of the disease. The difference in the levels of antibodies against monomeric C-reactive protein during flare and remission, and above all positive biopsy staining, supports their pathogenic role in this disease.